Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
1001645-58-4
|
| gptkbp:developedBy |
gptkb:Sirtris_Pharmaceuticals
|
| gptkbp:has_research_use |
potential cancer therapy
potential anti-aging agent potential metabolic disease treatment potential neurodegenerative disease treatment |
| gptkbp:hasInChIKey |
QJQYQKZKJXJZQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C24H22N6OS
|
| gptkbp:hasSMILES |
C1CN(CCN1)CC2=CC=CC(=C2)C3=CSC(=N3)NC(=O)/C=C/C4=CN=C5C=CC=CC5=C4
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRT1720
|
| gptkbp:is_not_approved_for_human_use |
true
|
| gptkbp:is_SIRT1_activator |
true
|
| gptkbp:IUPACName |
(E)-N-(2-(3-(piperazin-1-ylmethyl)phenyl)thiazol-4-yl)-3-(quinolin-3-yl)acrylamide
|
| gptkbp:mechanismOfAction |
SIRT1 activation
|
| gptkbp:molecularWeight |
442.54 g/mol
|
| gptkbp:PubChem_CID |
25154815
23355113 CHEMBL1800127 |
| gptkbp:relatedTo |
SRT1460
SRT2104 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
experimental
|
| gptkbp:bfsParent |
gptkb:SIRT1
|
| gptkbp:bfsLayer |
7
|